404 related articles for article (PubMed ID: 17164762)
41. VEGF-C, VEGF-D and VEGFR-3 expression in peripheral neuroblastic tumours.
Ramani P; Nash R; Radevsky L; Patel A; Luckett M; Rogers C
Histopathology; 2012 Dec; 61(6):1006-16. PubMed ID: 22804730
[TBL] [Abstract][Full Text] [Related]
42. Glucocorticoids suppress tumor lymphangiogenesis of prostate cancer cells.
Yano A; Fujii Y; Iwai A; Kawakami S; Kageyama Y; Kihara K
Clin Cancer Res; 2006 Oct; 12(20 Pt 1):6012-7. PubMed ID: 17062674
[TBL] [Abstract][Full Text] [Related]
43. Inhibition of VEGFR-3 activation with the antagonistic antibody more potently suppresses lymph node and distant metastases than inactivation of VEGFR-2.
Roberts N; Kloos B; Cassella M; Podgrabinska S; Persaud K; Wu Y; Pytowski B; Skobe M
Cancer Res; 2006 Mar; 66(5):2650-7. PubMed ID: 16510584
[TBL] [Abstract][Full Text] [Related]
44. [Characterization of markers and growth factors for lymphatic endothelium].
Waś H
Postepy Biochem; 2005; 51(2):209-14. PubMed ID: 16209358
[TBL] [Abstract][Full Text] [Related]
45. Distinct architecture of lymphatic vessels induced by chimeric vascular endothelial growth factor-C/vascular endothelial growth factor heparin-binding domain fusion proteins.
Tammela T; He Y; Lyytikkä J; Jeltsch M; Markkanen J; Pajusola K; Ylä-Herttuala S; Alitalo K
Circ Res; 2007 May; 100(10):1468-75. PubMed ID: 17478733
[TBL] [Abstract][Full Text] [Related]
46. Vascular endothelial growth factor receptor 3 is involved in tumor angiogenesis and growth.
Laakkonen P; Waltari M; Holopainen T; Takahashi T; Pytowski B; Steiner P; Hicklin D; Persaud K; Tonra JR; Witte L; Alitalo K
Cancer Res; 2007 Jan; 67(2):593-9. PubMed ID: 17234768
[TBL] [Abstract][Full Text] [Related]
47. Expression of VEGF-C and its receptor VEGFR-3 in the bone marrow of patients with acute myeloid leukaemia.
Liersch R; Schliemann C; Bieker R; Hintelmann H; Buechner T; Berdel WE; Mesters RM
Leuk Res; 2008 Jun; 32(6):954-61. PubMed ID: 18006056
[TBL] [Abstract][Full Text] [Related]
48. Interactions between sphingosine-1-phosphate and vascular endothelial growth factor signalling in ML-1 follicular thyroid carcinoma cells.
Balthasar S; Bergelin N; Löf C; Vainio M; Andersson S; Törnquist K
Endocr Relat Cancer; 2008 Jun; 15(2):521-34. PubMed ID: 18509004
[TBL] [Abstract][Full Text] [Related]
49. VEGF-C is associated with lymphatic status and invasion in oral cancer.
Siriwardena BS; Kudo Y; Ogawa I; Udagama MN; Tilakaratne WM; Takata T
J Clin Pathol; 2008 Jan; 61(1):103-8. PubMed ID: 17351086
[TBL] [Abstract][Full Text] [Related]
50. Vascular endothelial growth factor-D is correlated with hepatic metastasis from gastric cancer after radical gastrectomy.
Deng J; Liang H; Sun D; Pan Y; Wang B; Guo Y
Surgery; 2009 Nov; 146(5):896-905. PubMed ID: 19744460
[TBL] [Abstract][Full Text] [Related]
51. Plasmin activates the lymphangiogenic growth factors VEGF-C and VEGF-D.
McColl BK; Baldwin ME; Roufail S; Freeman C; Moritz RL; Simpson RJ; Alitalo K; Stacker SA; Achen MG
J Exp Med; 2003 Sep; 198(6):863-8. PubMed ID: 12963694
[TBL] [Abstract][Full Text] [Related]
52. VEGF-D in association with VEGFR-3 promotes nodal metastasis in human invasive lobular breast cancer.
van Iterson V; Leidenius M; von Smitten K; Bono P; Heikkilä P
Am J Clin Pathol; 2007 Nov; 128(5):759-66. PubMed ID: 17951197
[TBL] [Abstract][Full Text] [Related]
53. Cooperative and redundant roles of VEGFR-2 and VEGFR-3 signaling in adult lymphangiogenesis.
Goldman J; Rutkowski JM; Shields JD; Pasquier MC; Cui Y; Schmökel HG; Willey S; Hicklin DJ; Pytowski B; Swartz MA
FASEB J; 2007 Apr; 21(4):1003-12. PubMed ID: 17210781
[TBL] [Abstract][Full Text] [Related]
54. Further evidence for expression and function of the VEGF-C/VEGFR-3 axis in cancer cells.
Su JL; Chen PS; Chien MH; Chen PB; Chen YH; Lai CC; Hung MC; Kuo ML
Cancer Cell; 2008 Jun; 13(6):557-60. PubMed ID: 18538739
[No Abstract] [Full Text] [Related]
55. VEGFR-3, VEGF-C and VEGF-D mRNA quantification by RT-PCR in different human cell types.
Leclers D; Durand K; Cook-Moreau J; Rabinovitch-Chable H; Sturtz FG; Rigaud M
Anticancer Res; 2006; 26(3A):1885-91. PubMed ID: 16827121
[TBL] [Abstract][Full Text] [Related]
56. Calcium carbonate nanoparticle delivering vascular endothelial growth factor-C siRNA effectively inhibits lymphangiogenesis and growth of gastric cancer in vivo.
He XW; Liu T; Chen YX; Cheng DJ; Li XR; Xiao Y; Feng YL
Cancer Gene Ther; 2008 Mar; 15(3):193-202. PubMed ID: 18202713
[TBL] [Abstract][Full Text] [Related]
57. Vascular endothelial growth factor C--a potent risk factor in childhood acute lymphoblastic leukaemia: an immunocytochemical approach.
Nowicki M; Ostalska-Nowicka D; Kaczmarek E; Miskowiak B; Witt M
Histopathology; 2006 Aug; 49(2):170-7. PubMed ID: 16879394
[TBL] [Abstract][Full Text] [Related]
58. [Expression and clinical significance of vascular endothelial growth factor C and D in nasopharyngeal carcinoma].
Zhao GG; Xiang XJ; He YJ
Ai Zheng; 2007 Jan; 26(1):90-5. PubMed ID: 17222375
[TBL] [Abstract][Full Text] [Related]
59. Coexpression of VEGF-C and COX-2 and its association with lymphangiogenesis in human breast cancer.
Zhang XH; Huang DP; Guo GL; Chen GR; Zhang HX; Wan L; Chen SY
BMC Cancer; 2008 Jan; 8():4. PubMed ID: 18190720
[TBL] [Abstract][Full Text] [Related]
60. Association between expression of vascular endothelial growth factor C, chemokine receptor CXCR4 and lymph node metastasis in colorectal cancer.
Fukunaga S; Maeda K; Noda E; Inoue T; Wada K; Hirakawa K
Oncology; 2006; 71(3-4):204-11. PubMed ID: 17641542
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
